TORL BioTherapeutics Announces Initial Results of Novel Claudin 6 (CLDN6) Targeted Antibody Drug Conjugate (ADC) TORL-1-23 Selected for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - TORL BioTherapeutics LLC